-
All major moving averages are currently flat, typically a sign of consolidation or range-bound movement in the Nifty 50, said Sudeep Shah of SBI Securities.
-
An exchange filing by Glenmark said that it has received approval from the Drugs Controller General of India (DCGI) to commence patient enrollment and dosing in India.
-
The uptrend is expected to strengthen if the frontline indices decisively surpass short- and medium-term moving averages. Below are some short-term trading ideas to consider.
-
Motilal Oswal is bullish on Glenmark Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated August 18, 2025.
-
Glenmark Pharmaceuticals shares fell up to 4 percent in trade on August 18, after the pharma player's earnings show for the June quarter disappointed.
-
The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.
-
About 1510 shares advanced, 2341 shares declined, and 150 shares were unchanged.
-
Motilal Oswal is bullish on Glenmark Pharma recommended buy rating on the stock with a target price of Rs 2430 in its research report dated July 11, 2025.
-
Institutional bets pay off big as Glenmark Pharma locks into upper circuit after AbbVie licensing deal
-
The licensing deal is the largest one by any Indian pharma company, and the deal value is above expectations, said Nomura.
-
AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
-
Glenmark is in an extreme overbought zone as per RSI range shift rules. Hence, Sudeep Shah of SBI Securities believes it is likely to slide into the period of consolidation for the short term.
-
The market is expected to continue its rangebound trading in the upcoming sessions amid the ongoing Middle East conflict. Below are some short-term trading ideas to consider.
-
The momentum is expected to sustain in the upcoming session, though some profit booking at higher levels cannot be ruled out. Below are some short-term trading ideas to consider.
-
Motilal Oswal is bullish on Glenmark Pharma recommended buy rating on the stock with a target price of Rs 1690 in its research report dated May 26, 2025.
-
-
Glenmark Pharma: Despite strong growth in Europe and domestic formulations, muted demand in India and pressure in diabetes products weighed on overall performance
-
However, Nifty's move towards 24,200 would not be in a linear manner as bouts of volatility in the backdrop of looming US tariff announcement would prevail wherein, according to Dharmesh Shah of ICICI Securities.
-
The market may extend gains amid likely consolidation. Below are some trading ideas for the near term.
-
The market is expected to continue its northward journey. Below are some trading ideas for the near term.
-
-
Stocks To Watch, Feb 17: Stocks like Narayana Hrudayalaya, Dilip Buildcon, NRB Bearings, Rail Vikas Nigam, Borosil Renewables, Aditya Birla Fashion & Retail, La Opala RG, Dish TV India, Gujarat Narmada Valley Fertilizers and Chemicals, Easy Trip Planners, Wipro,Ujjivan Small Finance Bank, and Shriram Finance will be in focus on February 17.
-
Catch up on the latest stock market updates!
-
IQVIA, a US-based company that provides advanced analytics for the life sciences business, said the one-year sales data for Vimpat Oral Solution 10 mg/ml till October approximately $57 million.
-
Positive clinical trails results strengthen the case for approval of Glenmark Pharma's blood cancer drug. If successful, it could turn into a huge revenue opportunity for the company.
